ID

12765

Beschreibung

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00754312

Link

https://clinicaltrials.gov/show/NCT00754312

Stichworte

  1. 21.12.15 21.12.15 -
Hochgeladen am

21. Dezember 2015

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00754312

Eligibility Breast Cancer NCT00754312

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
is scheduled for breast biopsy due to a suspicious mass palpable or ≥1 cm on mammogram
Beschreibung

breast biopsy; mammogram

Datentyp

boolean

Alias
UMLS CUI [1]
C0405352
UMLS CUI [2]
C0024671
must be able to receive two doses of study medication 7 days apart prior to surgery
Beschreibung

Medication dose study

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0008972
has histologically confirmed invasive breast cancer with er positive, er and/or pr negative histology or triple negative (for er, pr, her-2) histology
Beschreibung

Invasive breast carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0853879
has an ecog performance status ≤ 2
Beschreibung

ecog performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
has no clinically significant laboratory or cardiac abnormalities
Beschreibung

abnormalities laboratory; abnormalities cardiac

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C0022877
UMLS CUI [2,1]
C1704258
UMLS CUI [2,2]
C0018787
has a negative serum pregnancy test at screening as is either post menopausal, sterile or willing to use an approved method of contraception.
Beschreibung

pregnancy test; Postmenopause

Datentyp

boolean

Alias
UMLS CUI [1]
C0032976
UMLS CUI [2]
C0206159
is able to swallow and retain oral medication
Beschreibung

oral medication

Datentyp

boolean

Alias
UMLS CUI [1]
C0175795
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
has a concomitant medical condition that precludes adequate study treatment compliance or assessment, such as: a. bleeding disorders that would increase risks of additional core biopsy for biomarkers, b. morbid obesity
Beschreibung

comorbidity; Hemorrhage; obesity

Datentyp

boolean

Alias
UMLS CUI [1]
C0009488
UMLS CUI [2]
C0019080
UMLS CUI [3]
C0028754
is currently receiving treatment with a medication on the prohibited medication list
Beschreibung

concomitant medication

Datentyp

boolean

Alias
UMLS CUI [1]
C2347852
has allergy to benzamides or inactive components of study drug
Beschreibung

hypersensitivity benzamides

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0005029
is participating in another clinical trial or has received another investigational agent within 30 days prior to informed consent
Beschreibung

Study Subject Participation Status

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568

Ähnliche Modelle

Eligibility Breast Cancer NCT00754312

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
breast biopsy; mammogram
Item
is scheduled for breast biopsy due to a suspicious mass palpable or ≥1 cm on mammogram
boolean
C0405352 (UMLS CUI [1])
C0024671 (UMLS CUI [2])
Medication dose study
Item
must be able to receive two doses of study medication 7 days apart prior to surgery
boolean
C3174092 (UMLS CUI [1,1])
C0008972 (UMLS CUI [1,2])
Invasive breast carcinoma
Item
has histologically confirmed invasive breast cancer with er positive, er and/or pr negative histology or triple negative (for er, pr, her-2) histology
boolean
C0853879 (UMLS CUI [1])
ecog performance status
Item
has an ecog performance status ≤ 2
boolean
C1520224 (UMLS CUI [1])
abnormalities laboratory; abnormalities cardiac
Item
has no clinically significant laboratory or cardiac abnormalities
boolean
C1704258 (UMLS CUI [1,1])
C0022877 (UMLS CUI [1,2])
C1704258 (UMLS CUI [2,1])
C0018787 (UMLS CUI [2,2])
pregnancy test; Postmenopause
Item
has a negative serum pregnancy test at screening as is either post menopausal, sterile or willing to use an approved method of contraception.
boolean
C0032976 (UMLS CUI [1])
C0206159 (UMLS CUI [2])
oral medication
Item
is able to swallow and retain oral medication
boolean
C0175795 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
comorbidity; Hemorrhage; obesity
Item
has a concomitant medical condition that precludes adequate study treatment compliance or assessment, such as: a. bleeding disorders that would increase risks of additional core biopsy for biomarkers, b. morbid obesity
boolean
C0009488 (UMLS CUI [1])
C0019080 (UMLS CUI [2])
C0028754 (UMLS CUI [3])
concomitant medication
Item
is currently receiving treatment with a medication on the prohibited medication list
boolean
C2347852 (UMLS CUI [1])
hypersensitivity benzamides
Item
has allergy to benzamides or inactive components of study drug
boolean
C0020517 (UMLS CUI [1,1])
C0005029 (UMLS CUI [1,2])
Study Subject Participation Status
Item
is participating in another clinical trial or has received another investigational agent within 30 days prior to informed consent
boolean
C2348568 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video